NAMRU EURAFCENT Partners with Seek Labs to Advance Field-Deployable Technologies for Warfighter Readiness
In May, Naval Medical Research Unit (NAMRU) EURAFCENT entered into two cooperative research and development agreements (CRADAs) with Seek Labs.
Archive
All News
Every update, milestone, and publication from Seek Labs.
-
-
Seek Labs and NAMRU EURAFCENT Enter CRADA to Evaluate Field-Deployable Diagnostics for Infectious Diseases
Seek Labs and NAMRU EURAFCENT have entered a CRADA to evaluate field-deployable molecular diagnostics for infectious disease detection and biosurveillance.
-
AI Can Design Viruses. Can Our Defenses Adapt Fast Enough?
AI-designed viruses are becoming a reality. Learn how programmable CRISPR could help build faster defenses against emerging and engineered viral threats.
-
ANINA: Molecular Accuracy Without the Laboratory.
Discover how Seek Labs developed ANINA™, a novel isothermal amplification chemistry for molecular accuracy without laboratory infrastructure.
-
Seek Labs Announces Publication in Nature Communications Validating ANINA™, a Room-Temperature, Instrument-Free Amplification Diagnostic Technology Designed to Deliver PCR-Level Sensitivity at the Point of Need
Data support SeekIt™, the Company’s molecular diagnostic platform’s, potential to eliminate the long-standing tradeoff between molecular performance, speed and accessibility.
-
Annexing isothermal nucleotide amplification enables probe-guided amplification and direct detection at ambient temperature
Isothermal nucleic acid amplification offers advantages over qPCR for decentralized diagnostics but remains constrained by rigid primer design, detection complexity, and equipment dependence.
-
BIO 2026: Where Pharma Leaders say AI Hasn’t Delivered
BIO 2026: Where Pharma leaders Say AI Hasn’t Delivered AI hasn’t always been what it was cracked up to be in pharma. Here’s where execs say the technology hasn’t lived up to the hype. SAN DIEGO — AI adoption is still ticking up in pharma with 34% of companies leveraging the tech for specific functions,…
-
Panel Discusses Future of US Public Health System After Major Federal Layoffs
Panel Discusses Future of US Public Health System After Major Federal Layoffs The future of the U.S. public health system was debated by experts on June 23 during a panel at the BIO International Convention in San Diego, as recent government restructuring and staff cuts have left agencies like the Centers for Disease Control and…
-
BIO 2026: US Public Health As We Know It Is Gone. Can We Rebuild a Better System?
Can the US public health system be rebuilt? Former FDA, CDC & NIH leaders discuss dismantling of HHS & the path to rebuilding public health.
-
The Map Isn’t the Milestone. What It Unlocks Is.
Seek Labs recently announced BioSeeker has mapped CRISPR-addressable regions across all 25 viral families known to infect humans. That is an important infectious disease milestone.
-
Seek Labs Maps 25/25 Viral Families through BioSeeker, Advancing a New Model for Sequence-Directed Antiviral Discovery
Seek Labs Maps 25/25 Viral Families through BioSeeker, Advancing a New Model for Sequence-Directed Antiviral Discovery The company’s comprehensive viral target atlas is designed to move development from reactive crisis response toward proactive, pre-identified genomic vulnerability mapping June 8, 2026 SALT LAKE CITY, UT (Business Wire) — Seek Labs, a private TechBio company building programmable…
-
Ebola Isn’t One Virus. We’ve Been Treating It Like One.
Ebola Isn’t One Virus. We’ve Been Treating It Like One. By Jared Bauer, CEO Ebola Bundibugyo (BDBV) is the strain driving the current outbreak in the Democratic Republic of the Congo and Uganda — and it is one the world is dangerously unprepared for. “No vaccine exists. No therapy exists. The virus circulated undetected for…
Stay connected
Follow the work as it unfolds.
Stay connected to company milestones, scientific insights, and the work unfolding across BioSeeker, SAT, and Seek Diagnostics.